On June 22, AbbVie announced an agreement to acquire immunology-focused biopharma firm Apogee Therapeutics for $10.1 billion (net of cash acquired). The deal is expected to close in the third quarter. AbbVie shares rose 6%.
AbbVie's next-generation immunology drugs targeting the IL-23 (Skyrizi) and JAK (Rinvoq) pathways are mitigating biosimilar headwinds to older blockbuster Humira.
AbbVie has had to depend on acquisitions to boost its late-stage pipeline, suggesting less successful internal research and development activities.
|
Metric
|
ABBV
|
LLY
|
JNJ
|
|---|---|---|---|
Price/Earnings (Normalized) | 24.99 | 42.00 | 24.91 |
Price/Book Value | — | 35.39 | 7.92 |
Price/Sales | 7.19 | 15.36 | 6.75 |
Price/Cash Flow | 19.70 | 41.29 | 21.84 |
|
Metric
|
ABBV
|
LLY
|
JNJ
|
|---|---|---|---|
Quick Ratio | 0.52 | 0.72 | 0.77 |
Current Ratio | 0.80 | 1.50 | 1.03 |
Interest Coverage | 2.96 | — | 24.09 |
|
Metric
|
ABBV
|
LLY
|
JNJ
|
|---|---|---|---|
Return on Assets (Normalized) | 13.37% | 24.73% | 13.33% |
Return on Equity (Normalized) | — | 114.33% | 32.77% |
Return on Invested Capital (Normalized) | 29.17% | 40.96% | 20.14% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|j?wDf#Gw | LOCK|bTS | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|@dtTDSC | LOCK|Lx | $619B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|%NCZ^@%q | LOCK|!m | $333B | |||
| Merck & Co Inc
MRK
| LOCK|@@Yrl%& | LOCK|Fr | $305B | |||
| Novartis AG ADR
NVS
| LOCK|?!Rcy&@ | LOCK|H! | $294B | |||
| AstraZeneca PLC
AZN
| LOCK|lS@cF<& | LOCK|@v | $267B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|Px?<HJCY | LOCK|?Vj | $218B | |||
| Amgen Inc
AMGN
| LOCK|xtSd%CV | LOCK|w&n | $196B | |||
| Gilead Sciences Inc
GILD
| LOCK|sJZ$Mf& | LOCK|Cf | $161B |
/author-service-images-prod-us-east-1.publishing.aws.arc.pub/morningstar/558ccc7b-2d37-4a8c-babf-feca8e10da32.jpg)
United States